Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AmBisome Prophylaxis in AML
NCT00451711Phase 2Unknown
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amphotericin b in invasive fungal infection (IFI) (3 arms). Primary endpoint: Incidence of all adverse events. Status: unknown.
02
Drugs
amphotericin b
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00451711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451711.